What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Black triangle. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 41042/0042.


RINVOQ 15 mg prolonged-release tablets (Great Britain)

Package leaflet: Information for the patient

RINVOQ 15 mg prolonged-release tablets

upadacitinib

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What RINVOQ is and what it is used for
2. What you need to know before you take RINVOQ
3. How to take RINVOQ
4. Possible side effects
5. How to store RINVOQ
6. Contents of the pack and other information

1. What RINVOQ is and what it is used for

RINVOQ contains the active substance upadacitinib. It belongs to a group of medicines called Janus kinase inhibitors. RINVOQ works by reducing the activity of an enzyme called ‘Janus kinase’ in the body, which helps to reduce inflammation.

RINVOQ is used for the treatment of the following inflammatory diseases:

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis

Rheumatoid Arthritis

RINVOQ is used to treat adults with rheumatoid arthritis. Rheumatoid arthritis is a disease that causes inflamed joints. If you have moderate to severe active rheumatoid arthritis, you may first be given other medicines, one of which will usually be methotrexate. If these medicines do not work well enough, you will be given RINVOQ either alone or in combination with methotrexate to treat your rheumatoid arthritis.

RINVOQ can help to reduce pain, stiffness and swelling in your joints, reduce tiredness and it can slow down damage to the bone and cartilage in your joints. These effects can ease your normal daily activities and so improve your quality of life.

Psoriatic Arthritis

RINVOQ is used to treat adults with psoriatic arthritis. Psoriatic arthritis is a disease that causes inflamed joints and psoriasis. If you have active psoriatic arthritis, you may first be given other medicines. If these medicines do not work well enough, you will be given RINVOQ either alone or in combination with methotrexate to treat your psoriatic arthritis.

RINVOQ can help to reduce pain, stiffness, and swelling in and around your joints, pain and stiffness in your spine, psoriatic skin rash, and tiredness, and it can slow down damage to the bone and cartilage in your joints. These effects can ease your normal daily activities and so improve your quality of life.

Ankylosing Spondylitis

RINVOQ is used to treat adults with ankylosing spondylitis. Ankylosing spondylitis is a disease that primarily causes inflammation in the spine. If you have active ankylosing spondylitis, you may first be given other medicines. If these medicines do not work well enough, you will be given RINVOQ to treat your ankylosing spondylitis.

RINVOQ can help to reduce back pain, stiffness, and inflammation in your spine. These effects can ease your normal daily activities and so improve your quality of life.

2. What you need to know before you take RINVOQ

Do not take RINVOQ

  • if you are allergic to upadacitinib or any of the other ingredients of this medicine (listed in section 6)
  • if you have a severe infection (such as pneumonia or bacterial skin infection)
  • if you have active tuberculosis (TB)
  • if you have severe liver problems
  • if you are pregnant (see section Pregnancy, breast-feeding and contraception)

Warnings and precautions

Talk to your doctor or pharmacist before and during treatment with RINVOQ if:

  • you have an infection (fever, sweating, or chills, shortness of breath, warm, red, or painful skin or sores on your body, feeling tired, cough, burning sensation when you pass urine or passing urine more often than normal, severe headache with stiff neck), or if you have ever had an infection that keeps coming back – RINVOQ can reduce your body’s ability to fight infections and so may worsen an infection that you already have, or make it more likely for you to get a new infection
  • you have had tuberculosis or have been in close contact with someone with tuberculosis. Your doctor will test you for tuberculosis before starting RINVOQ and may retest during treatment
  • you have had a herpes zoster infection (shingles), because RINVOQ may allow it to come back. Tell your doctor if you get a painful skin rash with blisters as these can be signs of shingles
  • you have ever had hepatitis B or C
  • you have recently had or plan to have a vaccination (immunisation) - this is because live vaccines are not recommended while using RINVOQ
  • you have cancer - because your doctor will have to decide if you can still be given RINVOQ
  • you are at high risk of developing skin cancer, your doctor may recommend preventive measures such as regular skin examinations while taking RINVOQ. Talk to your doctor if you develop a new lesion or any change in the appearance of an area on the skin. Some patients receiving RINVOQ have developed skin cancers
  • you have heart problems, high blood pressure, or high cholesterol
  • your liver does not work as well as it should
  • you have had blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism). Tell your doctor if you get a painful swollen leg, chest pain, or shortness of breath as these can be signs of blood clots in the veins.

Blood tests

You will need blood tests before you start taking RINVOQ, or while you are taking it. This is to check for a low red blood cell count (anaemia), low white blood cell count (neutropaenia or lymphopaenia), high blood fat (cholesterol) or high levels of liver enzymes. The tests are to check that treatment with RINVOQ is not causing problems.

Children and adolescents

RINVOQ is not recommended for use in children and adolescents under 18 years of age. This is because it has not been studied in this age group.

Other medicines and RINVOQ

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because some medicines may reduce how well RINVOQ works or may increase the risk of getting side effects. It is very important to talk to your doctor or pharmacist if you are taking any of the following:

  • medicines to treat fungal infections (such as itraconazole, posaconazole or voriconazole)
  • medicines to treat bacterial infections (such as clarithromycin)
  • medicines to treat Cushing’s syndrome (such as ketoconazole)
  • medicines to treat tuberculosis (such as rifampicin)
  • medicines to treat seizures or fits (such as phenytoin)
  • medicines that affect your immune system (such as azathioprine, ciclosporin and tacrolimus)

If any of the above apply to you or you are not sure, talk to your doctor or pharmacist before taking RINVOQ.

Pregnancy, breast-feeding and contraception

Pregnancy

RINVOQ must not be used during pregnancy.

Breast-feeding

If you are breast-feeding or are planning to breast-feed, talk to your doctor before taking this medicine. You should not use RINVOQ while breast-feeding as it is not known if this medicine passes into breast milk. You and your doctor should decide if you will breast-feed or use RINVOQ. You should not do both.

Contraception

If you are a woman of child-bearing potential, you must use effective contraception to avoid becoming pregnant while taking RINVOQ and for at least 4 weeks after your last dose of RINVOQ. If you become pregnant during this time, you must talk to your doctor straight away.

Driving and using machines

RINVOQ has no effect on the ability to drive and use machines.

3. How to take RINVOQ

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is one 15 mg tablet once a day.

  • Swallow the tablet whole with water. Do not split, crush, chew or break the tablet before swallowing as it may change how much medicine gets into your body.
  • To help you remember to take RINVOQ, take it at the same time every day.
  • The tablets can be taken with or without food.

If you take more RINVOQ than you should

If you take more RINVOQ than you should, contact your doctor. You may get some of the side effects listed in section 4.

If you forget to take RINVOQ

  • If you miss a dose, take it as soon as you remember.
  • If you forget your dose for an entire day, just skip the missed dose and take only a single dose as usual the following day.
  • Do not take a double dose to make up for a forgotten tablet.

If you stop taking RINVOQ

Do not stop taking RINVOQ unless your doctor tells you to stop taking it.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, RINVOQ can cause side effects, although not everybody gets them.

Serious side effects

Talk to your doctor or get medical help straight away if you get any signs of infection such as:

  • shingles or painful skin rash with blisters (herpes zoster) – common (may affect up to 1 in 10 people)
  • infection of the lung (pneumonia), which may cause shortness of breath, fever, and a cough with mucus – uncommon (may affect up to 1 in 100 people)

Other side effects

Talk to your doctor if you notice any of the following side effects:

Very common (may affect more than 1 in 10 people)

  • throat and nose infections

Common (may affect up to 1 in 10 people)

  • cough
  • fever
  • cold sores (herpes simplex)
  • feeling sick in the stomach (nausea)
  • increase in an enzyme called creatine kinase, shown by blood tests
  • low white blood cell counts shown in blood tests
  • increased levels of cholesterol (a type of fat in the blood) as shown in tests
  • increased levels of liver enzymes, shown by blood tests (sign of liver problems)
  • weight gain
  • acne

Uncommon (may affect up to 1 in 100 people)

  • thrush in the mouth (white patches in the mouth)
  • increased levels of triglycerides (a type of fat) in the blood, as shown in tests

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:

United Kingdom

Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard

or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store RINVOQ

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and carton after ‘EXP’.

This medicine does not require any special temperature storage conditions.

Store in original blister to protect from moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What RINVOQ contains

  • The active substance is upadacitinib. Each prolonged-release tablet contains 15 mg of upadacitinib (as upadacitinib hemihydrate).
  • The other ingredients are:
    • Core tablet: microcrystalline cellulose, mannitol, tartaric acid, hypromellose, silica colloidal anhydrous, magnesium stearate.
    • Film coating: poly(vinyl alcohol), macrogol, talc, titanium dioxide, iron oxide red (E172), iron oxide black (E172).

What RINVOQ looks like and contents of the pack

RINVOQ 15 mg prolonged-release tablets are purple, oblong, biconvex tablets imprinted on one side with ‘a15’.

The tablets are provided in blisters or bottles.

RINVOQ is available in packs containing 28 or 98 prolonged-release tablets and in multipacks of 84 comprising 3 cartons, each containing 28 prolonged-release tablets.

Each calendar blister contains 7 tablets.

RINVOQ is available in bottles with desiccant containing 30 prolonged-release tablets, each pack contains 1 bottle (30 tablet pack) or 3 bottles (90 tablet pack).

Not all pack sizes may be marketed.

Marketing Authorisation Holder

AbbVie Ltd.
Maidenhead
SL6 4UB
UK

Manufacturer

AbbVie S.r.l.
S.R. 148 Pontina
km 52 SNC
04011 Campoverde di Aprilia (Latina)
Italy

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
AbbVie Ltd
Tel: +44 (0)1628 561090

This leaflet was last revised in 01/2021

Other sources of information

Detailed and updated information on this product is available by scanning the QR code included below or on the outer carton with a smart phone. The same information is also available on the following URL: www.rinvoq.eu.

To listen to or request a copy of this leaflet in Braille, large print or audio, please contact the local representative of the Marketing Authorisation Holder.